Ara-290 (10mg)

About Ara-290 peptide​

ARA-290 is a non-erythropoietic EPO analogue engineered to retain tissue-protective and anti-inflammatory properties while minimizing effects on red blood cell production and cardiovascular parameters. By targeting specific EPO-related receptor complexes (often referred to as IRR/TPR), ARA-290 is used to explore:

• Modulation of inflammatory cytokine release
• Protection and repair of vascular and endothelial cells
• Regulation of immune-cell activity and antigen presentation
• Neural repair mechanisms and small fiber nerve integrity
• Wound repair and tissue regeneration in ischemic or inflammatory environments

Preclinical and translational research has examined ARA-290 in models of vascular injury, islet transplantation, autoimmune conditions, neuropathic pain, and small fiber neuropathy, making it a versatile tool for studying tissue protection and immune modulation.

Ara-290 peptide​ Scientific Research

Blood Vessel and Endothelial Health

Retinal and systemic ischemic injury models have highlighted the importance of endothelial colony forming cells (ECFCs) in vascular repair. ARA-290 has been studied for its ability to:

• Protect ECFCs from inflammation-induced damage
• Enhance ECFC proliferation, migration, and survival
• Improve homing of ECFCs to injured or ischemic regions of the vasculature

These findings support the use of ARA-290 as a probe for mechanisms underlying vascular regeneration and microvascular repair. Research also suggests that ARA-290 may help improve the performance and durability of transplanted ECFCs, a key interest in regenerative medicine and vascular engineering models.

Inflammatory Cytokines and Islet Cell Survival

In models of islet cell transplantation, ARA-290 has been investigated for its potential to modulate inflammatory responses that typically limit graft survival. Studies in mice have shown that:

• ARA-290 can reduce macrophage activation and lessen the secretion of pro-inflammatory cytokines such as IL-6, IL-12, and TNF-α
• Reduced inflammatory signaling correlates with improved survival and function of transplanted islet cells

Mechanistically, these effects are linked to ARA-290 binding to tissue-protective receptor complexes, leading to decreased apoptosis, enhanced tissue protection, and more favorable local immune profiles. These results are experimental and focused on understanding how selective immune modulation can improve cell transplant outcomes.

Tissue Protection and Repair

ARA-290’s tissue-protective activity has been demonstrated across multiple preclinical models of injury and inflammation. Engagement of the TPR/IRR is associated with:

• Reduced apoptotic cell death in stressed tissues
• Diminished levels of damaging inflammatory cytokines
• Enhanced tissue regeneration, faster wound closure, and reduced scar formation in experimental wound models

These properties have led to significant interest in ARA-290 as a tool compound to study the biology of injury response, wound repair, and organ protection under ischemic or inflammatory conditions, particularly in the context of metabolic diseases such as diabetes.

Immune System Modulation

The TPR is expressed on several immune cell types, including macrophages, dendritic cells, mast cells, and T cells. ARA-290 has been used to interrogate how selective receptor targeting can reshape immune responses:

• In macrophages, ARA-290 reduces secretion of TNF-α and IL-6, which can limit excessive inflammation while still permitting pathogen control in many settings.
• ARA-290 influences chemokine signaling, reducing recruitment of inflammatory cells while supporting the activity of resident tissue macrophages involved in repair.
• Studies suggest that ARA-290 can modulate antigen presentation by dendritic cells, potentially altering adaptive immune responses and graft rejection pathways.

These immune-modulating properties have prompted investigations of ARA-290 in experimental models of colitis, systemic lupus erythematosus (SLE), and other autoimmune or inflammatory conditions. In certain lupus models, ARA-290 has been associated with reduced autoantibody levels and improved kidney parameters, illustrating its utility in studying targeted immune modulation.

Neuropathic Pain and Small Fiber Neuropathy

One of the most advanced areas of ARA-290 research relates to neuropathic pain and small fiber neuropathy:

• ARA-290 acts on the innate repair receptor, and emerging data indicate that it can also inhibit TRPV1 channel activity (the capsaicin/heat receptor), a key mediator of burning and heat-related pain.
• Studies in subjects with small fiber neuropathy (e.g., associated with sarcoidosis or metabolic disease) have reported increases in intraepidermal nerve fiber density and reductions in pain scores following ARA-290 exposure in controlled settings.
• These effects have led to clinical development of ARA-290 (also known as cibinetide) in neuropathic pain indications, including sarcoid neuropathy and diabetic neuropathy, under regulated investigational protocols.

In research contexts, ARA-290 therefore serves as a powerful tool to explore the relationship between immune signaling, nerve fiber integrity, and chronic neuropathic pain mechanisms.

Orphan and Translational Development Context

ARA-290 (cibinetide) has received orphan drug designation in specific neuropathic conditions and has progressed into mid- and late-stage clinical trials in those settings. From a research perspective, this makes ARA-290 particularly relevant in:

• Translational neuropathy models
• Chronic inflammatory and autoimmune pain syndromes
• Diabetic wound-healing and impaired tissue repair models

While these developments highlight its translational potential, ARA-290 supplied as a research peptide remains intended solely for non-clinical experimental use.

Ara-290 peptide​ FAQ

Q1: What is ARA-290 in a research context?
A1: ARA-290 is a non-erythropoietic peptide derived from erythropoietin, used in research to study tissue protection, immune modulation, vascular repair, and neuropathic pain mechanisms via the innate repair/tissue-protective receptor pathways.

Q2: What are the main experimental applications of ARA-290?
A2: Common research applications include models of vascular and endothelial repair, islet transplantation, autoimmune and inflammatory diseases, neuropathic pain, small fiber neuropathy, and wound healing in metabolic disease.

Q3: How does ARA-290 differ from full-length erythropoietin (EPO)?
A3: ARA-290 is designed to selectively activate tissue-protective receptor complexes without stimulating the hematopoietic and many cardiovascular effects associated with full-length EPO, making it more suitable for focused tissue-protection and immune-modulation research.

Q4: Is ARA-290 intended for human or veterinary use?
A4: No. ARA-290 from research suppliers is for laboratory use only and is not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any condition.

Q5: Why is ARA-290 of interest in neuropathy research?
A5: ARA-290 has been studied for its effects on small nerve fiber integrity, inflammatory signaling, and TRPV1-related pain pathways, making it a valuable compound for investigating mechanisms underlying neuropathic pain and small fiber neuropathy in controlled studies.